Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.
4 registered trials, newest registry update first. Showing only trials linked to Bimagrumab.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese NCT05616013 | Bimagrumab | Phase 2 | Completed | Eli Lilly and Company | 507 | May 16, 2024 | Jul 8, 2026 |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight NCT06643728 | Bimagrumab | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | Jan 16, 2026 | May 26, 2026 |
| A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes NCT06901349 | Bimagrumab | Phase 2 | Withdrawn | Eli Lilly and Company | – | Jun 10, 2025 | Sep 24, 2025 |
| Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients NCT01925209 | Bimagrumab | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 251 | Jan 6, 2016 | Aug 11, 2017 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.